Genentech : FDA Approves Tecentriq as Adjuvant Treatment for Certain Lung Cancer Patients

By Stephen Nakrosis

Genentech on Friday said the Food and Drug Administration approved its Tencentriq as an adjuvant treatment for certain lung cancer patients.

The company said Tencentriq, or atezolizumab, was approved as adjuvant treatment following surgery and platinum-based chemotherapy for certain adults with Stage II-IIIA non-small cell lung cancer.

Genentech said Tecentriq is the first and only cancer immunotherapy available for adjuvant treatment of NSCLC.

The company said the approval was based on results from interim analysis of the Phase III IMpower010 study, which showed treatment with Tecentriq improved disease-free survival by over one-third in PD-L1-positive Stage II-IIIA lung cancer, compared with the best supportive care.

Genentech is a member of the Roche Group.

Write to Stephen Nakrosis at [e-mail]

(END) Dow Jones Newswires

10-15-21 1305ET